|Day Low/High||7.73 / 7.99|
|52 Wk Low/High||1.92 / 8.78|
Treatment of aHUS patients with CCX168 effective in reducing aHUS serum-induced thrombus formation
Company expects additional data including progression-free survival by the end of 2016
Investors in ChemoCentryx, Inc. saw new options become available this week, for the February 2017 expiration.
PRIME designation designed to provide path to expedite clinical development and accelerate marketing authorization applications
These under-$10 stocks are within range of triggering big breakout trades.
Psoriasis Treatment via Inhibition of Chemokine Receptor CCR6 Supported by In Vivo Model Data
Potentiation of anti-tumor effect observed with combination of small molecule chemokine receptor CCR1 inhibitor and PD-L1 checkpoint inhibitor in triple negative breast cancer model
These stocks look ready to break out and trade much higher from current levels.